MX2015001508A - El uso de antitrombina en la oxigenacion por membrana extracorporea. - Google Patents

El uso de antitrombina en la oxigenacion por membrana extracorporea.

Info

Publication number
MX2015001508A
MX2015001508A MX2015001508A MX2015001508A MX2015001508A MX 2015001508 A MX2015001508 A MX 2015001508A MX 2015001508 A MX2015001508 A MX 2015001508A MX 2015001508 A MX2015001508 A MX 2015001508A MX 2015001508 A MX2015001508 A MX 2015001508A
Authority
MX
Mexico
Prior art keywords
antithrombin
extracorporeal membrane
membrane oxygenation
oxygenation
extracorporeal
Prior art date
Application number
MX2015001508A
Other languages
English (en)
Spanish (es)
Inventor
Johan Frieling
Simon Lowry
Original Assignee
Lfb Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lfb Usa Inc filed Critical Lfb Usa Inc
Publication of MX2015001508A publication Critical patent/MX2015001508A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2015001508A 2012-08-03 2013-08-02 El uso de antitrombina en la oxigenacion por membrana extracorporea. MX2015001508A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261679345P 2012-08-03 2012-08-03
PCT/US2013/053365 WO2014022748A1 (en) 2012-08-03 2013-08-02 The use of antithrombin in extracorporeal membrane oxygenation

Publications (1)

Publication Number Publication Date
MX2015001508A true MX2015001508A (es) 2015-04-08

Family

ID=50028554

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001508A MX2015001508A (es) 2012-08-03 2013-08-02 El uso de antitrombina en la oxigenacion por membrana extracorporea.

Country Status (13)

Country Link
US (1) US9511087B2 (enExample)
EP (1) EP2879697A4 (enExample)
JP (1) JP6389172B2 (enExample)
KR (1) KR20150039201A (enExample)
CN (1) CN104884080A (enExample)
AR (1) AR091977A1 (enExample)
AU (1) AU2013296240B2 (enExample)
BR (1) BR112015002321A2 (enExample)
CA (1) CA2879763C (enExample)
IL (1) IL236776A0 (enExample)
MX (1) MX2015001508A (enExample)
TW (1) TW201425332A (enExample)
WO (1) WO2014022748A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501365A1 (en) 2010-12-30 2013-09-16 Laboratoire Francais Du Fractionnment Et Des Biotechnologies Glycols as pathogen inactivating agents
AR091977A1 (es) 2012-08-03 2015-03-11 Revo Biolog Inc El uso de antitrombina en la oxigenacion de membranas extracorporeas
BR112015019341A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
JP2016532100A (ja) 2013-07-05 2016-10-13 ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ アフィニティークロマトグラフィーマトリックス
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3388140A1 (en) * 2017-04-10 2018-10-17 Gambro Lundia AB Extracorporeal blood circuit

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
US6727405B1 (en) 1986-04-09 2004-04-27 Genzyme Corporation Transgenic animals secreting desired proteins into milk
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5439446A (en) 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
DE4028800A1 (de) 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
DE4326665C2 (de) 1993-08-09 1995-07-13 Biotest Pharma Gmbh Verfahren zur Sterilfiltration von Milch
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US5801063A (en) 1995-05-09 1998-09-01 Grandics; Peter Device and process for the biospecific removal of heparin
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
EP0973934A4 (en) 1997-02-25 2003-02-05 Genzyme Transgenics Corp TRANSGEN PRODUCED NON-SECRETED PROTEINS.
US20060264357A1 (en) 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
DE10159556A1 (de) 2001-12-05 2003-06-12 Aventis Behring Gmbh Intellect Antithrombin III zur Präventation und Therapie vaskuloproliferativer Erkrankungen
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
JP2007503838A (ja) 2003-09-05 2007-03-01 ジーティーシー バイオセラピューティクス， インコーポレイティド トランスジェニック動物の乳汁中での融合タンパク質の産生方法
CA2479968A1 (en) 2004-09-01 2006-03-01 Keith R. Walley Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome
WO2006007213A1 (en) 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
AU2006261555A1 (en) 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
WO2007014244A2 (en) 2005-07-25 2007-02-01 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
NZ568433A (en) 2005-10-21 2012-07-27 Gtc Biotherapeutics Inc Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US20070292407A1 (en) 2005-12-12 2007-12-20 The Board Of Trustees Operating Michigan State University Methods of treatment for meconium aspiration syndrome
US7531632B2 (en) 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
WO2007124019A2 (en) 2006-04-21 2007-11-01 Gtc Biotherapeutics, Inc. Methods and products related to the transfer of molecules from blood to the mammary gland
US20100016173A1 (en) 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
US20110082083A1 (en) 2009-04-10 2011-04-07 Gtc Biotherapeutics, Inc. Formulations of liquid stable antithrombin
US8551096B2 (en) 2009-05-13 2013-10-08 Boston Scientific Scimed, Inc. Directional delivery of energy and bioactives
BR112014000217A2 (pt) 2011-07-07 2017-02-07 Revo Biologics Inc formulação e método para a criação de uma formulação que estabiliza a proteína terapêutica
TW201400499A (zh) 2012-03-12 2014-01-01 Revo Biolog Inc 抗凝血酶用於治療妊娠毒血症之用途
AR091977A1 (es) 2012-08-03 2015-03-11 Revo Biolog Inc El uso de antitrombina en la oxigenacion de membranas extracorporeas

Also Published As

Publication number Publication date
US20140194360A1 (en) 2014-07-10
CA2879763A1 (en) 2014-02-06
EP2879697A4 (en) 2016-01-20
AU2013296240B2 (en) 2018-05-17
EP2879697A1 (en) 2015-06-10
CA2879763C (en) 2020-12-01
TW201425332A (zh) 2014-07-01
JP6389172B2 (ja) 2018-09-12
KR20150039201A (ko) 2015-04-09
AU2013296240A1 (en) 2015-02-12
US9511087B2 (en) 2016-12-06
IL236776A0 (en) 2015-03-31
JP2015524823A (ja) 2015-08-27
BR112015002321A2 (pt) 2019-10-22
AR091977A1 (es) 2015-03-11
WO2014022748A1 (en) 2014-02-06
CN104884080A (zh) 2015-09-02

Similar Documents

Publication Publication Date Title
MX2015001508A (es) El uso de antitrombina en la oxigenacion por membrana extracorporea.
BR112015012014A2 (pt) proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
MY174894A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
WO2011106376A3 (en) Use of microvesicles in the treatment of medical conditions
MX2021001867A (es) Administracion y monitoreo de oxidio nitrico en fluidos ex vivo.
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
WO2010091376A3 (en) Devices and methods for perfusion therapy
UA111148C2 (uk) Сигма-ліганди для застосування при профілактиці і/або лікуванні післяопераційного болю
EP4488289A3 (en) Long-acting coagulation factors and uses thereof
ZA201402745B (en) Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and the use thereof.
MX347620B (es) Derivados de sulfonilaminopirrolidinona, su preparacion y aplicacion terapeutica.
WO2012053823A3 (ko) 인자 ix 활성을 갖는 융합 단백질
MX344189B (es) Formulaciones de mazindol.
WO2011163512A3 (en) Cancer therapy
EA201390925A1 (ru) Производные санглиферина и способы их получения
MX2013009456A (es) Compuestos de azufre aromaticos sustituidos y metodos para su uso.
MX2012012930A (es) Composicion farmaceutica topica que comprende heparina.
MX351765B (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.
WO2012135746A3 (en) Methods and devices comprising extracorporeal blood flow
UA97741C2 (ru) Способ восстановления кожных покровов при глубоких распространенных ожогах микроаутодермотрансплантатами
JO3333B1 (ar) استعمال 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium أو ملح مقبول دوائيا منه للوقاية من السكري وعلاجه
UA65220U (ru) Способ гемостаза при проведении хирургического вмешательства на щитовидной железе